Gilead Sciences (GILD) EBITDA (2009 - 2026)
Gilead Sciences (GILD) posted EBITDA of -$9.7 billion for Q2 2026, compared with $3.17 billion a year earlier.
Gilead Sciences (GILD) EBITDA (2009 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA at Gilead Sciences was $263 million, down 97.6% year-over-year; for FY2025, it came in at $12.78 billion, up 188.6% from FY2024.
- Annual EBITDA shows a five-year compound annual growth rate of 18.2% (FY2020 to FY2025).
- In prior years, Gilead Sciences' EBITDA was $4.43 billion in FY2024 (-57.0%), $10.3 billion in FY2023 (+9.2%), $9.43 billion in FY2022 (-21.2%) and $11.97 billion in FY2021 (+115.6%).
- The Q2 2026 figure stands as the lowest quarterly EBITDA in data going back to Q1 2009.
- On a year-over-year basis, EBITDA increased in three of the last six quarters, with growth averaging 21.7%.
- The strongest year-over-year quarter for EBITDA in the past five years was Q1 2023, with growth of 224.8%; the weakest was Q1 2022, with a decline of 78.5%.
- According to Business Quant data, EBITDA for the three prior quarters was $3.28 billion (Q1 2026), $2.67 billion (Q4 2025) and $4.01 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 9.10 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 8.33 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 999.00 Mn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 5.09 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 4.63 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -9.70 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 5.89 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 1.30 Bn |
| 10 | Bristol Myers Squibb | 128.45 Bn | 79.72 Bn | 9.25 Bn | 954.00 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.70 Bn |
| Mar 31, 2026 | 3.28 Bn |
| Dec 31, 2025 | 2.67 Bn |
| Sep 30, 2025 | 4.01 Bn |
| Jun 30, 2025 | 3.17 Bn |
| Mar 31, 2025 | 2.93 Bn |
| Dec 31, 2024 | 3.15 Bn |
| Sep 30, 2024 | 1.58 Bn |
| Jun 30, 2024 | 3.34 Bn |
| Mar 31, 2024 | -3.63 Bn |
| Dec 31, 2023 | 2.30 Bn |
| Sep 30, 2023 | 3.31 Bn |
| Jun 30, 2023 | 2.35 Bn |
| Mar 31, 2023 | 2.35 Bn |
| Dec 31, 2022 | 2.80 Bn |
| Sep 30, 2022 | 3.36 Bn |
| Jun 30, 2022 | 2.55 Bn |
| Mar 31, 2022 | 722.00 Mn |
| Dec 31, 2021 | 1.48 Bn |
| Sep 30, 2021 | 4.37 Bn |
Gilead Sciences EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda&ticker=GILD&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda", "ticker": "GILD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda&ticker=GILD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();